Literature DB >> 33878485

Mid-Term Results of Arthroscopically-Assisted Latissimus Dorsi Transfer for Irreparable Posterosuperior Rotator Cuff Tears.

Manuel Waltenspül1, Benedikt Jochum2, Lukas Filli3, Lukas Ernstbrunner2, Karl Wieser2, Dominik Meyer2, Christian Gerber2.   

Abstract

INTRODUCTION: With the progress in arthroscopic surgery, latissimus dorsi transfer (LDT) for irreparable posterosuperior rotator cuff tears (RCTs) has become a reliable all-arthroscopic or arthroscopically-assisted procedure. Mid-term results of the arthroscopically-assisted LDT (aLDT) are scarce in literature. The purpose of this study was to report our clinical and radiographic mid-term results of aLDT for irreparable posterosuperior RCTs.
METHODS: Thirty-one consecutive patients with a mean age of 55.5 (Range, 38-73) years at the time of aLDT were evaluated after a mean of 3.5 (range, 2-5) years. All patients had irreparable, full-thickness tears of at least the complete supraspinatus +/- infraspinatus tendons and 14 patients (45%) had undergone previous rotator cuff repair. Seven patients (23%) needed a concomitant upper-third subscapularis repair at the time of aLDT. Mid-term results were assessed clinically and radiographically (including MRI).
RESULTS: At final follow-up, four failures (14%) had undergone revision to reverse total shoulder arthroplasty (RTSA) essentially for untreatable pain. Patients revised to RTSA, had significantly higher preoperative pain levels (Constant pain scores: 6 points vs. 11 points; p=0.032) and lower Constant Score (CS) activity scores (2 points vs. 5 points; p=0.017) than the remaining 27 patients. Patients with failed previous rotator cuff repairs had significantly inferior results than patients without previous repair (mean SSV% 66 vs 88; p = 0.035) For the 27 non-revised patients, the mean relative CS improved from 63% to 76% (p=0.032), Constant pain scores from 10.5 to 12.7 (p=0.012) points and the Subjective Shoulder Value from 43% to 77% (p<0.001). Significant progression of glenohumeral arthropathy by two or more grades according to Hamada was observed in thirteen (48%) out of the 27 patients, but there was no significant difference in clinical outcome between the patients with (n=13) and those without arthropathy (n=14; p=0.923).
CONCLUSIONS: Mid-term results of the arthroscopically-assisted latissimus dorsi transfer for irreparable posterosuperior RCTs is associated with significant improvement in objective and subjective outcome measures. The failure rate leading to conversion to RTSA is relatively high in this cohort. The failures were associated with unusually intense pain in low demand individuals and / or revision of failed rotator cuff repair. Long-term result of aLDT are needed to evaluate the effect of this procedure on progression of OA.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Year:  2021        PMID: 33878485     DOI: 10.1016/j.jse.2021.03.149

Source DB:  PubMed          Journal:  J Shoulder Elbow Surg        ISSN: 1058-2746            Impact factor:   3.019


  4 in total

1.  Technical Guide and Tips to Posterior Arthroscopic Latissimus Dorsi Transfer for Irreparable Posterosuperior Rotator Cuff Tears.

Authors:  Vanesa Lopez-Fernandez; Sandrine Mariaux; Laurent Lafosse; Thibault Lafosse
Journal:  Arthrosc Tech       Date:  2022-04-22

2.  Relationship between the Hamada Grade and underlying pathological conditions in the rotator cuff and long head of biceps in symptomatic patients with rotator cuff tears.

Authors:  Akihiko Hasegawa; Teruhisa Mihata; Kunimoto Fukunishi; Akihiro Uchida; Masashi Neo
Journal:  JSES Int       Date:  2022-02-18

3.  [Latissimus dorsi transfer with a modified single-incision Herzberg technique and description of its arthroscopic advancement].

Authors:  M M Schneider; M Moursy; C Gerhardt; M Kimmeyer; V Rentschler; L J Lehmann
Journal:  Oper Orthop Traumatol       Date:  2022-02-04       Impact factor: 1.154

Review 4.  Tendon transfers for massive rotator cuff tears.

Authors:  Antonio Cartucho
Journal:  EFORT Open Rev       Date:  2022-05-31
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.